Autopsy report · NCT03646188

Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)

“Application of arrays was inconsistent.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 10 months before it started.
• Ran for about 11 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

SkinJect, Inc.

Sponsor type

Industry

Conditions

Basal Cell Carcinoma

Interventions

Placebo-containing MNA; 25 µg doxorubicin-containing MNA; 50 µg doxorubicin-containing MNA; 100 µg doxorubicin-containing MNA; 200 µg doxorubicin-containing MNA

Participants

13

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.